FDA Inspection 1218990 — InvaGen Pharmaceuticals, Inc.

InvaGen Pharmaceuticals, Inc. — FEI 3012696190

The FDA completed an inspection of InvaGen Pharmaceuticals, Inc. on September 19, 2023 in Central Islip, NY. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 19, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Central Islip, NY (United States)